Expansion of Genetic Testing Revenue
First written in FY2025-H1. 3 of 5 entries say "Advanced", first in FY2025. Latest entry: 2026-08-06.
2 other companies' latest entry also says "Advanced".
- 2026-08-06AdvancedEarnings
「The clinical laboratory business increased revenue due to growth in routine testing, higher testing revenue in the genetics field as a growth initiative, and progress in optimizing selling prices.」
Expansion of testing revenue in the genetics field continued to be identified as a factor behind the increase in first-quarter revenue in the clinical laboratory business. - FY2026AdvancedAnnual report
「The LSIM business posted higher revenue, reflecting an increase in testing revenue in the genetics field, which the Company is pursuing as a growth initiative, in addition to the impact of the inappropriate incident being contained below expectations.」
Higher testing revenue in the genetics field became a factor behind the full-year increase in LSIM revenue, with the initiative continuing to contribute to performance. - FY2026-H1RestatedAnnual report
「The LSIM business posted a slight increase in revenue, mainly due to higher testing revenue in the genetics field, which the Company is pursuing as a growth initiative.」
The Company continued to pursue higher testing revenue in the genetics field as a growth initiative, making it a factor behind the slight increase in LSIM revenue in the interim period under review. - FY2025AdvancedAnnual report
「Revenue in the LSIM business was on par with the same period of the previous year, reflecting an increase in general testing and higher testing revenue in the genetics field, which the Company is pursuing as a growth initiative, despite declines in specialised testing and COVID-19-related testing.」
For the full fiscal year, the Company confirmed that increases in general testing and testing revenue in the genetics field offset declines in specialised testing and COVID-19-related testing. - FY2025-H1First statedAnnual report
「Revenue in the LSIM business was on par with the same period of the previous year, reflecting an increase in general testing and higher testing revenue in the genetics field, which the Company is pursuing as a growth initiative, despite declines in specialised testing and COVID-19-related testing.」
The Company newly stated that it is working to expand testing revenue in the genetics field as a growth initiative to offset declines in specialised testing and COVID-19-related testing.